Cargando…
Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study
Objectives: The impact of non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and tumor necrosis factor inhibitors (TNFi) on the outcomes of mild-moderate COVID-19 in patients with ankylosing spondylitis (AS) remains unclear. This s...
Autores principales: | Li, Yan, Hu, Zhengyuan, Guo, Yufei, Zhao, Zheng, Li, Kunpeng, Wang, Xiuru, Zhang, Jie, Liang, Dongfeng, Zhang, Jianglin, Hu, Xiaoyue, Zhu, Jian, Huang, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642246/ https://www.ncbi.nlm.nih.gov/pubmed/37964869 http://dx.doi.org/10.3389/fphar.2023.1266915 |
Ejemplares similares
-
Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
por: Kim, Se Hee, et al.
Publicado: (2021) -
Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China
por: Ji, Xiaojian, et al.
Publicado: (2019) -
Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China
por: Man, Siliang, et al.
Publicado: (2020) -
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
por: Ji, Xiaojian, et al.
Publicado: (2019) -
Non-steroidal Anti-inflammatory Drugs Are Unlikely to Inhibit Radiographic Progression of Ankylosing Spondylitis: A Systematic Review
por: Zhang, Jing-Ru, et al.
Publicado: (2019)